Alyeska Investment Group, L.P. Gilead Sciences, Inc. Transaction History

Alyeska Investment Group, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $14.3 Million - $16.3 Million	-184,527 Reduced 22.33%	641,805 $53.3 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $21.7 Million - $31.1 Million	-347,635 Reduced 29.61%	826,332 $70.9 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $19.6 Million - $22.4 Million	-329,710 Reduced 21.93%	1,173,967 $72.4 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $56.1 Million - $63.2 Million	972,263 Added 182.96%	1,503,677 $92.9 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $29.4 Million - $36.8 Million	506,756 Added 2055.14%	531,414 $31.6 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $75.6 Million - $88.2 Million	-1,165,501 Reduced 97.93%	24,658 $1.75 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $86.7 Million - $106 Million	1,190,159 New	1,190,159 $89.7 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.